Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
Eli Lilly and Company
Michelle Petri; Ian N Bruce; Thomas Dörner; Yoshiya Tanaka; Eric F Morand; Kenneth C Kalunian; Mario H Cardiel; Maria E Silk; Christina L Dickson; Gabriella Meszaros; Lu Zhang; Bochao Jia; Youna Zhao; Conor J McVeigh; Marta Mosca